Core Insights - NurExone Biologic Inc. is advancing its first-in-class exosome-based therapy, ExoPTEN, for acute spinal cord injuries, with plans to initiate a Phase 1/2a clinical trial in 2026 [2][6][11] - The company will present updates on its clinical plans and preclinical study results at the upcoming American Spinal Injury Association meeting [4][8] Company Developments - Professor Nahshon Knoller, a senior clinical advisor, will discuss the 2026 SCI Trial and preclinical results at the ASIA meeting [4][5] - The 2026 SCI Trial will enroll adult patients with traumatic spinal cord injuries classified as ASIA Grade A or B, treating them within 3 to 7 days post-injury [3][6] - The trial will consist of a Phase 1 dose-escalation study for safety in up to 18 patients, followed by a Phase 2a randomized, double-blind, placebo-controlled trial measuring functional recovery in 10-15 patients [3] Product and Technology - ExoPTEN is based on mesenchymal stem cell-derived exosomes loaded with siRNA targeting PTEN, aimed at reducing cell death and promoting axonal regrowth [6][11] - The therapy has received Orphan Drug Designation from both the FDA and EMA, facilitating its clinical trial roadmap [6][11] - Preclinical studies have shown robust recovery of motor, sensory, and structural functions in rat models, confirming the therapeutic effects of ExoPTEN [7][11] Market Context - The company is positioned in the multi-billion-dollar markets for treating acute spinal cord and optic nerve injuries [11] - NurExone has established a U.S. subsidiary, Exo-Top Inc., to support its North American growth strategy [11]

Core Insights - NurExone Biologic Inc. is a preclinical-stage biotechnology company focused on exosome-based therapies for central nervous system injuries, recently announcing its financial results for Q1 2025 and corporate updates [1][10] Financial Performance - The company reported a net loss of US$1.68 million for Q1 2025, an increase from a net loss of US$0.92 million in Q1 2024 [9] - Research and development expenses rose to US$0.62 million in Q1 2025 from US$0.23 million in Q1 2024, primarily due to non-cash stock-based compensation and increased subcontractor costs [8] - General and administrative expenses increased to US$1.08 million in Q1 2025 from US$0.70 million in Q1 2024, driven by higher legal and professional service costs [8] Capital Raising Activities - The company raised approximately C$480 thousand through a private placement of 856,996 units at $0.56 per unit on January 21, 2025 [5] - An additional C$866 thousand was raised through the exercise of Class A Warrants, with 2,140,456 warrants exercised at a price of $0.34 each [6] - On April 22, 2025, NurExone completed another private placement, raising approximately C$2.3 million, which will be used to advance clinical development activities [14] Business Developments - NurExone was included in the 2025 TSX Venture 50™ list, marking it as a top-performing company on the TSX Venture Exchange, with a 110% share price appreciation and a 209% increase in market cap [3] - The company established a U.S. subsidiary, Exo-Top Inc., to focus on the production and commercialization of exosomes, enhancing strategic flexibility and cost efficiency [4] Product Development - The lead product, ExoPTEN, has shown promising preclinical data for treating acute spinal cord and optic nerve injuries, with plans for first-in-human trials expected in 2026 [13][14] - Recent presentations at industry conferences highlighted significant advancements in optic nerve regeneration and facial nerve repair, validating the therapeutic potential of the ExoPTEN platform [14] Management Commentary - The CEO emphasized the company's progress in demonstrating functional recovery across various nerve injuries and the preparation for clinical trials [11] - The CFO noted that the financial results reflect disciplined investment in clinical programs and infrastructure, strengthening the cash position for advancing the ExoPTEN program [12]

Core Insights - NurExone Biologic Inc. is a preclinical-stage biotechnology company focused on exosome-based therapies for central nervous system injuries, with recent data on optic nerve regeneration presented at the ARVO Annual Meeting [1][5] Company Overview - NurExone's lead product, ExoPTEN, has shown promising preclinical data in restoring retinal activity and improving optic nerve structure in a controlled rat model [2][4] - The company is developing therapies for acute glaucoma and spinal cord injuries, with ExoPTEN demonstrating a 75% success rate in restoring motor function in preclinical spinal cord studies [4][6] - NurExone has established a U.S. subsidiary, Exo-Top Inc., to support its North American growth strategy [6] Research and Development - The study presented at ARVO has been expanded to include a larger group of animals, indicating ongoing research efforts [2] - The company is exploring the use of ExoPTEN in treating optic nerve pathologies, particularly in glaucoma models [4] - The exosome-based product supports a modular and scalable approach to nervous system repair, with applications in spinal cord and facial nerve regeneration [4] Market Potential - The markets for acute spinal cord and optic nerve injuries are multi-billion-dollar opportunities, highlighting the economic significance of NurExone's therapies [6] - The therapy for acute glaucoma could provide both clinical and economic value by preserving vision and reducing healthcare costs associated with irreversible blindness [4][6] Industry Recognition - NurExone's participation in the ARVO Annual Meeting reflects the growing recognition of exosome-based strategies as a potential new frontier in regenerative medicine [5]

Core Insights - NurExone Biologic Inc. is enhancing its engagement with the European financial and healthcare sectors by participating in three significant events, following the announcement of a potential third therapeutic indication for its lead drug asset, ExoPTEN [1][5] Group 1: Upcoming Events and Participation - CEO Dr. Lior Shaltiel will represent NurExone at INVEST 2025 in Stuttgart, a key investment conference for German-speaking markets, where the company will present its corporate strategy and pipeline development [2][3] - NurExone is also participating in the Healthtech Roadshow in Zurich from May 5-8, 2025, aimed at engaging healthcare professionals and life science investors in Switzerland [3] - From May 12-15, 2025, Dr. Shaltiel will present at BioProcess International Europe in Hamburg, discussing the company's exosome-based siRNA therapy and its ExoTherapy platform [4] Group 2: Strategic Goals and Growth Narrative - The participation in these events is designed to increase visibility for NurExone's innovative approach to regenerative medicine, particularly with the identification of a third potential indication for ExoPTEN, which enhances the company's growth narrative [5] - NurExone plans to maintain an active presence at key European conferences throughout 2025 to strengthen investor relations and foster strategic collaborations in the healthcare and biotech sectors [6] Group 3: Company Overview and Product Focus - NurExone Biologic Inc. is focused on developing exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing promising preclinical data for treating spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [7] - The company has received Orphan Drug Designation, facilitating its roadmap towards clinical trials in the U.S. and Europe, and has established Exo-Top Inc. as a U.S. subsidiary to support its North American growth strategy [7]

Exosome-Based ExoPTEN Targets Three High-Value Nerve Injury IndicationsTORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries is presenting new data at the 2025 International Society for Extracellular Vesicles (ISEV) Annual Meeting being held in Vienna April 24-27. The ISEV presentation will feature ...